DocMorris continues its growth path
07.05.2014 12:46
The mail order pharmacy DocMorris can look back on a successful financial year. Over 3 million prescriptions have been processed and more than 2.5 million customers have so far ordered medicines and pharmacy products from Europe's largest mail-order pharmacy.
Overall, the mail order pharmacy increased sales last year by over three percent to around 335 million euros. “We have opened up new customer groups in the past year and now mainly look after chronically ill patients who need prescription medicines,” says CEO Olaf Heinrich, satisfied with the financial year.
“The result shows that customers remain loyal to DocMorris despite the discount ban. The growth in the delivery of over-the-counter medications via the Internet was particularly dynamic. This is clear evidence of the successful implementation of our newly defined eCommerce strategy.” According to DocMorris, DocMorris achieved a customer growth rate of around 50 percent in the OTC area and slight growth was also recorded in the Rx area, bucking the industry trend.
The company said that political and social commitment to modernizing the pharmacy market continued in the election year of 2013. Before the federal election, the mail-order pharmacy published the political manifesto “The New Pharmacy 2020” and took a position on questions of future pharmaceutical care. “With the idea of a mobile pharmacy, DocMorris also provided a concrete solution proposal for the impending undersupply in rural areas,” says a press release.
The realignment of the board was completed last year. As Chief Pharmaceutical Officer, Christian Franken will expand the areas of supply management, clinical pharmaceutical services and customer care. In the B2B sector, special chronic care programs are developed in collaboration with pharmaceutical companies and health insurance companies and implemented with a highly qualified team of pharmacists. As Chief Strategy Officer, Max Müller will strengthen the areas of Communications, Regulatory Affairs and Strategy Development and will drive the further development of the business model and the positioning of the brand among stakeholders. There are many growth prospects for pharmaceutical shipping, especially at the European level.